pharmaceutical investing CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results
pharmaceutical investing CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel
pharmaceutical investing CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection
pharmaceutical investing CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
pharmaceutical investing CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
pharmaceutical investing CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology Annual Meeting
pharmaceutical investing CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
pharmaceutical investing CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
Goldera Expands High-Grade E1 Gold Discovery with Two New Parallel Structures Ahead of Planned Q4 Drilling at Egan Gold Project
Oreterra CEO Letter to Shareholders Provides Forward Guidance on Trek South Drill Results in Advance of Assays
Renforth Intersects Broad Nickel-Cobalt and Zinc-Copper-Silver Mineralization in Victoria Undercut Drilling, Including 118.0 M of 0.081% Ni and 10.9 M of 0.544% Zn
